Towards tailored vaccine delivery: Needs, challenges and perspectives

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 363-376

  Amorij, Jean Pierre ^a   Kersten, Gideon F A ^a   Saluja, Vinay ^a   Tonnis, Wouter F ^b   Hinrichs, Wouter L J ^b   Slütter, Bram ^c   Bal, Suzanne M ^d   Bouwstra, Joke A ^e   Huckriede, Anke ^f   Jiskoot, Wim ^e  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adjuvant; Device; Formulation; Mucosal vaccination; Targeting; Transcutaneous vaccination

Indexed keywords

T-CELLS;

ADJUVANT; DEVICE; FORMULATION; MUCOSAL VACCINATION; TARGETING; TRANSCUTANEOUS VACCINATIONS;

VACCINES;

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; AVRIDINE; CALCIUM PHOSPHATE; CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; FLT3 LIGAND; GAMMA INTERFERON; GLYCOLIPID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7; LIPOSOME; LOXORIBINE; MIFAMURTIDE; MONTANIDE ISA 51; MURAMYL PEPTIDE; NANOPARTICLE; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR AGONIST; UNINDEXED DRUG; VACCINE; VIROSOME VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CYTOPLASM; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG STABILITY; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LACTOCOCCUS; LYMPH NODE; LYSOSOME; MICROPARTICLE ENZYME IMMUNOASSAY; MINIMALLY INVASIVE PROCEDURE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 84862678279     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.039     Document Type: Review

References (191)

1. Anonymous, Morbidity and Mortality Weekly Report 58 (2009).
2. D.T. O'Hagan, R. Rappuoli, Novel approaches to vaccine delivery, Pharm. Res. 21 (9) (2004) 1519-1530.
3. B. Guy, The perfect mix: recent progress in adjuvant research, Nat. Rev. Microbiol. 5 (7) (2007) 505-517.
4. R. Edelman, Vaccine adjuvants, Rev. Infect. Dis. 2 (3) (1980) 370-383.
5. F.R. Vogel,M.F. Powell, A compendiumof vaccine adjuvants and excipients, Vaccine Design. Series: Pharm. Biotechnol. 6 (1995) 141-228.
6. R. Edelman, An update on vaccine adjuvants in clinical trial, AIDS Res. Hum. Retroviruses 8 (8) (1992) 1409-1411.
7. E. Telzak, S.M. Wolff, C.A. Dinarello, T. Conlon, A. el Kholy, G.M. Bahr, J.P. Choay, A. Morin, L. Chedid, Clinical evaluation of the immunoadjuvant murabutide, a derivative of MDP, administered with a tetanus toxoid vaccine, J. Infect. Dis. 153 (3) (1986) 628-633.
8. J. Wintsch, C.L. Chaignat, D.G. Braun, M. Jeannet, H. Stalder, S. Abrignani, D. Montagna, F. Clavijo, P. Moret, J.M. Dayer, et al., Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine, J. Infect. Dis. 163 (2) (1991) 219-225.
9. C.L. Cooper, H.L. Davis, M.L. Morris, S.M. Efler, M.A. Adhami, A.M. Krieg, D.W. Cameron, J. Heathcote, CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study, J. Clin. Immunol. 24 (6) (2004) 693-701.
10. V. Appay, C. Jandus, V. Voelter, S. Reynard, S.E. Coupland, D. Rimoldi, D. Lienard, P. Guillaume, A.M. Krieg, J.C. Cerottini, P. Romero, S. Leyvraz, N. Rufer, D.E. Speiser, New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site, J. Immunol. 177 (3) (2006) 1670-1678.
11. C. Bode, G. Zhao, F. Steinhagen, T. Kinjo, D.M. Klinman, CpG DNA as a vaccine adjuvant, Expert Rev. Vaccines 10 (4) (2011) 499-511.
12. ClinicalTrials.gov, Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer (NCT00820144) (2009).
13. S.A. Frech, R.T. Kenney, C.A. Spyr, H. Lazar, J.F. Viret, C. Herzog, R. Gluck, G.M. Glenn, Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch, Vaccine 23 (7) (2005) 946-950.
14. J.A. Stoute, D.G. Heppner Jr., C.J. Mason, J. Siangla, M.O. Opollo, K.E. Kester, L. Vigneron, G. Voss, M.J. Walter, N. Tornieporth, J.D. Cohen, W.R. Ballou, Phase 1 safety and immunogenicity trial of malaria vaccine RTS, S/AS02A in adults in a hyperendemic region of western Kenya, Am. J. Trop. Med. Hyg. 75 (1) (2006) 166-170.
15. G.M. Glenn, D.N. Taylor, X. Li, S. Frankel, A. Montemarano, C.R. Alving, Transcutaneous immunization: a human vaccine delivery strategy using a patch, Nat. Med. 6 (12) (2000) 1403-1406.
16. ClinicalTrials.gov, Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator (NCT00175435) (2005).
17. S. Adams, D.W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C.M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, R.M. Holman, R.L. Shapiro, R.S. Berman, N. Berner, Y. Shao, O. Manches, L. Pan, R.R. Venhaus, E.W. Hoffman, A. Jungbluth, S. Gnjatic, L. Old, A.C. Pavlick, N. Bhardwaj, Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant, J. Immunol. 181 (1) (2008) 776-784.
18. R. Casalegno-Garduno, A. Schmitt, M. Schmitt, Clinical peptide vaccination trials for leukemia patients, Expert Rev. Vaccines 10 (6) (2011) 785-799.
19. M.A. Jacobson, E. Sinclair, B. Bredt, L. Agrillo, D. Black, C.L. Epling, A. Carvidi, T. Ho, R. Bains, V. Girling, S.P. Adler, Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12, Vaccine 24 (25) (2006) 5311-5319.
20. T.G. Evans, M. Hasan, L. Galibert, D. Caron, The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults, Vaccine 21 (3-4) (2002) 322-329.
21. C.R. Kensil, R. Kammer, QS-21: a water-soluble triterpene glycoside adjuvant, Expert Opin. Investig. Drugs 7 (9) (1998) 1475-1482.
22. I. Mbawuike, Y. Zang, R.B. Couch, Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant, Vaccine 25 (17) (2007) 3263-3269.
23. P.O. Livingston, S. Adluri, F. Helling, T.J. Yao, C.R. Kensil, M.J. Newman, D. Marciani, Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma, Vaccine 12 (14) (1994) 1275-1280.
24. P.B. Chapman, D.M.Morrissey, K.S. Panageas,W.B. Hamilton, C. Zhan, A.N. Destro, L. Williams, R.J. Israel, P.O. Livingston, Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+QS21 vaccine: a dose-response study, Clin. Cancer Res. 6 (3) (2000) 874-879.
25. O. Kashala, R. Amador, M.V. Valero, A. Moreno, A. Barbosa, B. Nickel, C.A. Daubenberger, F. Guzman, G. Pluschke, M.E. Patarroyo, Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21, Vaccine 20 (17-18) (2002) 2263-2277.
26. A. Ghochikyan, M. Mkrtichyan, I. Petrushina, N. Movsesyan, A. Karapetyan, D.H. Cribbs, M.G. Agadjanyan, Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch, Vaccine 24 (13) (2006) 2275-2282.
27. J.P. Stanfield, D. Gall, P.M. Bracken, Single-dose antenatal tetanus immunisation, Lancet 1 (7797) (1973) 215-219.
28. F.M. Davenport, Seventeen years' experience with mineral oil adjuvant influenza virus vaccines, Ann. Allergy 26 (6) (1968) 288-292.
29. C.H. Stuart-Harris, Adjuvant influenza vaccines, Bull. World Health Organ. 41 (3) (1969) 617-621.
30. F.C. Jensen, J.R. Savary, J.P. Diveley, J.C. Chang, Adjuvant activity of incomplete Freund's adjuvant, Adv. Drug Deliv. Rev. 32 (3) (1998) 173-186.
31. G.W. Beebe, A.H. Simon, S. Vivona, Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953, Am. J. Epidemiol. 95 (4) (1972) 337-346.
32. G.W. Beebe, A.H. Simon, S. Vivona, Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951-1953, Am. J. Med. Sci. 247 (1964) 385-406.
33. S.N. Markovic, V.J. Suman, J.N. Ingle, J.S. Kaur, H.C. Pitot, C.L. Loprinzi, R.D. Rao, E.T. Creagan,M.R. Pittelkow, J.B. Allred,W.K. Nevala, E. Celis, Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization, Am. J. Clin. Oncol. 29 (4) (2006) 352-360.
34. A. Gringeri, E. Santagostino, M. Muca-Perja, P.M. Mannucci, J.F. Zagury, B. Bizzini, A. Lachgar, M. Carcagno, J. Rappaport, M. Criscuolo, W. Blattner, A. Burny, R.C. Gallo, D. Zagury, Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients, J. Hum. Virol. 1 (4) (1998) 293-298.
35. G.W. Lawrence, A. Saul, A.J. Giddy, R. Kemp, D. Pye, Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720, Vaccine 15 (2) (1997) 176-178.
36. B. Genton, F. Al-Yaman, I. Betuela, R.F. Anders, A. Saul, K. Baea, M. Mellombo, J. Taraika, G.V. Brown, D. Pye, D.O. Irving, I. Felger, H.P. Beck, T.A. Smith, M.P. Alpers, Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children, Vaccine 22 (1) (2003) 30-41.
37. H. Toledo, A. Baly, O. Castro, S. Resik, J. Laferte, F. Rolo, L. Navea, L. Lobaina, O. Cruz, J. Miguez, T. Serrano, B. Sierra, L. Perez, M.E. Ricardo, M. Dubed, A.L. Lubian, M. Blanco, J.C. Millan, A. Ortega, E. Iglesias, E. Penton, Z. Martin, J. Perez, M. Diaz, C.A. Duarte, A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers, Vaccine 19 (30) (2001) 4328-4336.
38. C.A. Cano, The multi-epitope polypeptide approach in HIV-1 vaccine development, Genet. Anal. 15 (3-5) (1999) 149-153.
39. J.W. Smith, W.B. Fletcher, M. Peters, M. Westwood, F.J. Perkins, Response to influenza vaccine in adjuvant 65-4, J. Hyg. (Lond) 74 (2) (1975) 251-259.
40. N. Petrovsky, S. Heinzel, Y. Honda, A.B. Lyons, New-age Vaccine Adjuvants: Friend or Foe? Biopharm, International, 2007.
41. J. Treanor, C. Nolan, D. O'Brien, D. Burt, G. Lowell, J. Linden, L. Fries, Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects, Vaccine 24 (3) (2006) 254-262.
42. J.M. Langley, S.A. Halperin, S. McNeil, B. Smith, T. Jones, D. Burt, C.P. Mallett, G.H. Lowell, L. Fries, Safety and immunogenicity of a Proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults, Vaccine 24 (10) (2006) 1601-1608.
43. C. Moser, M. Amacker, R. Zurbriggen, Influenza virosomes as a vaccine adjuvant and carrier system, Expert Rev. Vaccines 10 (4) (2011) 437-446.
44. J. Weber, R. Cheinsong-Popov, D. Callow, S. Adams, G. Patou, K. Hodgkin, S. Martin, F. Gotch, A. Kingsman, Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers, Vaccine 13 (9) (1995) 831-834.
45. I.D. Davis, W. Chen, H. Jackson, P. Parente, M. Shackleton, W. Hopkins, Q. Chen, N. Dimopoulos, T. Luke, R. Murphy, A.M. Scott, E. Maraskovsky, G. McArthur, D. MacGregor, S. Sturrock, T.Y. Tai, S. Green, A. Cuthbertson, D. Maher, L. Miloradovic, S.V. Mitchell, G. Ritter, A.A. Jungbluth, Y.T. Chen, S. Gnjatic, E.W. Hoffman, L.J. Old, J.S. Cebon, Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans, Proc. Natl. Acad. Sci. U. S. A. 101 (29) (2004) 10697-10702.
46. E.A. McNeela, I. Jabbal-Gill, L. Illum, M. Pizza, R. Rappuoli, A. Podda, D.J. Lewis, K.H. Mills, Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan, Vaccine 22 (8) (2004) 909-914.
47. C. Firbas, B. Jilma, E. Tauber, V. Buerger, S. Jelovcan, K. Lingnau, M. Buschle, J. Frisch, C.S. Klade, Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects, Vaccine 24 (20) (2006) 4343-4353.
48. R.T. Kenney, A.S. Cross, in: M.M. Levine (Ed.), New Generation Vaccines, 4th edition, Informa healthcare, New York, London, 2010, pp. 250-262.
49. K.E. Kester, J.F. Cummings, O. Ofori-Anyinam, C.F. Ockenhouse, U. Krzych, P. Moris, R. Schwenk, R.A. Nielsen, Z. Debebe, E. Pinelis, L. Juompan, J. Williams, M. Dowler, V.A. Stewart, R.A. Wirtz, M.C. Dubois, M. Lievens, J. Cohen, W.R. Ballou, D.G. Heppner Jr., Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection, J. Infect. Dis. 200 (3) (2009) 337-346.
50. P.L. Alonso, J. Sacarlal, J.J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M.M. Navia, S. Corachan, M. Ceuppens, M.C. Dubois, M.A. Demoitie, F. Dubovsky, C. Menendez, N. Tornieporth, W.R. Ballou, R. Thompson, J. Cohen, Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial, Lancet 364 (9443) (2004) 1411-1420.
51. M.R. Withers, D. McKinney, B.R. Ogutu, J.N. Waitumbi, J.B. Milman, O.J. Apollo, O.G. Allen, K. Tucker, L.A. Soisson, C. Diggs, A. Leach, J. Wittes, F. Dubovsky, V.A. Stewart, S.A. Remich, J. Cohen, W.R. Ballou, C.A. Holland, J.A. Lyon, E. Angov, J.A. Stoute, S.K. Martin, D.G. Heppner Jr., Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children, PLoS Clin. Trials 1 (7) (2006) e32.
52. E. Macete, J.J. Aponte, C. Guinovart, J. Sacarlal, O. Ofori-Anyinam, I. Mandomando, M. Espasa, C. Bevilacqua, A. Leach, M.C. Dubois, D.G. Heppner, L. Tello, J. Milman, J. Cohen, F. Dubovsky, N. Tornieporth, R. Thompson, P.L. Alonso, Safety and immunogenicity of the RTS, S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique, Trop. Med. Int. Health 12 (1) (2007) 37-46.
53. J.A. Stoute,M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, P. Desmons, B.T. Wellde, N. Garcon, U. Krzych, M. Marchand, A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group, N. Engl. J. Med. 336 (2) (1997) 86-91.
54. S. McCormack, A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, A. Newberry, G. Jones, S. Lister, S. Beddows, R. Cheingsong, A. Rees, A. Babiker, J. Banatvala, C. Bruck, J. Darbyshire, D. Tyrrell, C. Van Hoecke, J. Weber, A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320, Vaccine 18 (13) (2000) 1166-1177.
55. N. Garcon, P. Chomez, M. Van Mechelen, GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives, Expert Rev. Vaccines 6 (5) (2007) 723-739.
56. D.T. O'Hagan, N.M. Valiante, Recent advances in the discovery and delivery of vaccine adjuvants, Nat. Rev. Drug Discov. 2 (9) (2003) 727-735.
57. D.F. Hoft, V. Brusic, I.G. Sakala, Optimizing vaccine development, Cell. Microbiol. 13 (7) (2011) 934-942.
58. L.B. Lawson, E.B. Norton, J.D. Clements, Defending the mucosa: adjuvant and carrier formulations for mucosal immunity, Curr. Opin. Immunol. 23 (3) (2011) 414-420.
59. V.E. Schijns, E.C. Lavelle, Trends in vaccine adjuvants, Expert Rev. Vaccines 10 (4) (2011) 539-550.
60. P. Moingeon, V. Lombardi, N. Saint-Lu, S. Tourdot, V. Bodo, L. Mascarell, Adjuvants and vector systems for allergy vaccines, Immunol. Allergy Clin. North Am. 31 (2) (2011) 407-419 xii.
61. D. Christensen, K.S. Korsholm, P. Andersen, E.M. Agger, Cationic liposomes as vaccine adjuvants, Expert Rev. Vaccines 10 (4) (2011) 513-521.
62. N. Petrovsky, P.D. Cooper, Carbohydrate-based immune adjuvants, Expert Rev. Vaccines 10 (4) (2011) 523-537.
63. R.M. Jacobson, A. Swan, A. Adegbenro, S.L. Ludington, P.C. Wollan, G.A. Poland, Making vaccines more acceptable-methods to prevent and minimize pain and other common adverse events associated with vaccines, Vaccine 19 (17-19) (2001) 2418-2427.
64. H. Kiyono, S. Fukuyama, NALT- versus Peyer's-patch-mediatedmucosal immunity, Nat. Rev. Immunol. 4 (9) (2004) 699-710.
65. C.S. Ambrose, C. Luke, K. Coelingh, Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza, Influenza Other Respi. Viruses 2 (6) (2008) 193-202.
66. J.P. Amorij, A. Huckriede, J. Wilschut, H.W. Frijlink, W.L. Hinrichs, Development of stable influenza vaccine powder formulations: challenges and possibilities, Pharm. Res. 25 (6) (2008) 1256-1273.
67. D. van Duin, A.C. Shaw, Toll-like receptors in older adults, J. Am. Geriatr. Soc. 55 (9) (2007) 1438-1444.
68. J.S. Park, S.Y. Park, H.I. Cho, H.J. Sohn, T.G. Kim, Enhanced induction of T cell immunity using dendritic cells pulsed with HIV Tat and HCMV-pp 65 fusion protein in vitro, Immune Netw. 11 (3) (2011) 182-189.
69. K. Kronenberg, S. Brosch, F. Butsch, Y. Tada, N. Shibagaki, M.C. Udey, E. von Stebut, Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major, J. Invest. Dermatol. 130 (11) (2010) 2602-2610.
70. V. Saini, V. Jain, M.S. Sudheesh, K.S. Jaganathan, P.K. Murthy, D.V. Kohli, Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen, Int. J. Pharm. 408 (1-2) (2011) 50-57.
71. J. Gasparri, L. Speroni, N.S. Chiaramoni, S. del Valle Alonso, Relationship between the adjuvant and cytotoxic effects of the positive charges and polymerization in liposomes, J. Liposome Res. 21 (2) (2011) 124-133.
72. N. Lincopan, N.M. Espindola, A.J. Vaz, M.H. da Costa, E. Faquim-Mauro, A.M. Carmona-Ribeiro, Novel immunoadjuvants based on cationic lipid: preparation, characterization and activity in vivo, Vaccine 27 (42) (2009) 5760-5771.
73. D.J. Kirby, I. Rosenkrands, E.M. Agger, P. Andersen, A.G. Coombes, Y. Perrie, PLGA microspheres for the delivery of a novel subunit TB vaccine, J. Drug Target. 16 (4) (2008) 282-293.
74. M. Tafaghodi, M.R. Jaafari, S.A. Tabassi, Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid, Curr. Drug Deliv. 5 (2) (2008) 108-113.
75. S.M. Bal, S. Hortensius, Z. Ding, W. Jiskoot, J.A. Bouwstra, Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination, Vaccine 29 (5) (2011) 1045-1052.
76. Z. Ding, S.M. Bal, S. Romeijn, G.F. Kersten,W. Jiskoot, J.A. Bouwstra, Transcutaneous immunization studies inmice using diphtheria toxoid-loaded vesicle formulations and a microneedle array, Pharm. Res. 28 (1) (2011) 145-158.
77. O.G. Gomez-Duarte, J. Galen, S.N. Chatfield, R. Rappuoli, L. Eidels, M.M. Levine, Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain, Vaccine 13 (16) (1995) 1596-1602.
78. R.P. Mazzantini, E.N. Miyaji, W.O. Dias, D. Sakauchi, A.L. Nascimento, I. Raw, N. Winter, B. Gicquel, R. Rappuoli, L.C. Leite, Adjuvant activity of Mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C, Vaccine 22 (5-6) (2004) 740-746.
79. C. Arigita, L. Bevaart, L.A. Everse, G.A. Koning, W.E. Hennink, D.J. Crommelin, J.G. van de Winkel, M.J. van Vugt, G.F. Kersten, W. Jiskoot, Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response, Infect. Immun. 71 (9) (2003) 5210-5218.
80. J.M. Irache, H.H. Salman, C. Gamazo, S. Espuelas, Mannose-targeted systems for the delivery of therapeutics, Expert Opin. Drug Deliv. 5 (6) (2008) 703-724.
81. Y. van Kooyk, T.B. Geijtenbeek, Toll-like receptors keep antigen sorting on the right track, Immunity 25 (4) (2006) 525-527.
82. Y. van Kooyk, G.A. Rabinovich, Protein-glycan interactions in the control of innate and adaptive immune responses, Nat. Immunol. 9 (6) (2008) 593-601.
83. T. Tsuji, J. Matsuzaki, M.P. Kelly, V. Ramakrishna, L. Vitale, L.Z. He, T. Keler, K. Odunsi, L.J. Old, G. Ritter, S. Gnjatic, Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity, J. Immunol. 186 (2) (2011) 1218-1227.
84. E. Stylianou, I. Pepponi, C.J. van Dolleweerd, M.J. Paul, J.K. Ma, R. Reljic, Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice, Vaccine 29 (12) (2011) 2279-2286.
85. S.L. Demento, A.L. Siefert, A. Bandyopadhyay, F.A. Sharp, T.M. Fahmy, Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines, Trends Biotechnol. 29 (6) (2011) 294-306.
86. J.E. Eyles, Therapeutic use of molecules that mimic pathogen danger signals, Endocr. Metab. Immune Disord. Drug Targets 7 (3) (2007) 177-186.
87. T. Nochi, H. Kiyono, Innate immunity in the mucosal immune system, Curr. Pharm. Des. 12 (32) (2006) 4203-4213.
88. M.H. Lahoud, F. Ahmet, S. Kitsoulis, S.S. Wan, D. Vremec, C.N. Lee, B. Phipson, W. Shi, G.K. Smyth, A.M. Lew, Y. Kato, S.N. Mueller, G.M. Davey, W.R. Heath, K. Shortman, I. Caminschi, Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype, J. Immunol. 187 (2) (2011) 842-850.
89. W.W. Unger, Y. van Kooyk, 'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells, Curr. Opin. Immunol. 23 (1) (2011) 131-137.
90. T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nat. Immunol. 11 (5) (2010) 373-384.
91. T. Kawai, S. Akira, Toll-like receptors and their crosstalk with other innate receptors in infection and immunity, Immunity 34 (5) (2011) 637-650.
92. M.F. Bachmann, G.T. Jennings, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol. 10 (11) (2010) 787-796.
93. P. Johansen, T. Storni, L. Rettig, Z. Qiu, A. Der-Sarkissian, K.A. Smith, V. Manolova, K.S. Lang, G. Senti, B. Mullhaupt, T. Gerlach, R.F. Speck, A. Bot, T.M. Kundig, Antigen kinetics determines immune reactivity, Proc. Natl. Acad. Sci. U. S. A. 105 (13) (2008) 5189-5194.
94. D.T. Brandau, L.S. Jones, C.M. Wiethoff, J. Rexroad, C.R. Middaugh, Thermal stability of vaccines, J. Pharm. Sci. 92 (2) (2003) 218-231.
95. D. Chen, D. Kristensen, Opportunities and challenges of developing thermostable vaccines, Expert Rev. Vaccines 8 (5) (2009) 547-557.
96. J. Rexroad, C.M. Wiethoff, L.S. Jones, C.R. Middaugh, Lyophilization and thermostability of vaccines, Cell Preserv. Technol. 1 (2) (2002) 91-104.
97. S.F. Ausar, T.R. Foubert, M.H. Hudson, T.S. Vedvick, C.R. Middaugh, Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature, J. Biol. Chem. 281 (28) (2006) 19478-19488.
98. S. Roy, I. Henderson, R. Nayar, T.W. Randolph, J.F. Carpenter, Effect of pHon stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations, J. Pharm. Sci. 97 (12) (2008) 5132-5146.
99. T. Estey, C. Vessely, T.W. Randolph, I. Henderson, L.J. Braun, R. Nayar, J.F. Carpenter, Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry, J. Pharm. Sci. 98 (9) (2009) 2994-3012.
100. C. Vessely, T. Estey, T.W. Randolph, I. Henderson, J. Cooper, R. Nayar, L.J. Braun, J.F. Carpenter, Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution, J. Pharm. Sci. 98 (9) (2009) 2970-2993.
101. S. Bai, M.C. Manning, T.W. Randolph, J.F. Carpenter, Aggregation of recombinant human botulinum protein antigen serotype C in varying solution conditions: implications of conformational stability for aggregation kinetics, J. Pharm. Sci. 100 (3) (2011) 836-848.
102. C. Arigita, W. Jiskoot, J. Westdijk, C. van Ingen, W.E. Hennink, D.J. Crommelin, G.F. Kersten, Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines, Vaccine 22 (5-6) (2004) 629-642.
103. B. Metz, G. van den Dobbelsteen, C. van Els, J. van der Gun, L. Levels, L. van der Pol, N. Rots, G. Kersten, Quality-control issues and approaches in vaccine development, Expert Rev. Vaccines 8 (2) (2009) 227-238.
104. J.P. Amorij, J. Meulenaar, W.L. Hinrichs, T. Stegmann, A. Huckriede, F. Coenen, H.W. Frijlink, Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying, Vaccine 25 (35) (2007) 6447-6457.
105. S.F. Ausar, M. Espina, J. Brock, N. Thyagarayapuran, R. Repetto, L. Khandke, C.R. Middaugh, High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles, Hum. Vaccin. 3 (3) (2007) 94-103.
106. L.D. Schlehuber, I.J. McFadyen, Y. Shu, J. Carignan, W.P. Duprex, W.R. Forsyth, J.H. Ho, C.M. Kitsos, G.Y. Lee, D.A. Levinson, S.C. Lucier, C.B. Moore, N.T. Nguyen, J. Ramos, B.A. Weinstock, J. Zhang, J.A. Monagle, C.R. Gardner, J.C. Alvarez, Towards ambient temperature-stable vaccines: the identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay, Vaccine 29 (31) (2011) 5031-5039.
107. V. Saluja, W.L. Hinrichs, H.W. Frijlink, Dried influenza vaccines: over the counter vaccines, Hum. Vaccin. 6 (10) (2010) 854-856.
108. W.L.J. Hinrichs, M.G. Prinsen, H.W. Frijlink, Inulin glasses for the stabilization of therapeutic proteins, Int. J. Pharm. 215 (1-2) (2001) 163-174.
109. R. Alcock, M.G. Cottingham, C.S. Rollier, J. Furze, S.D. De Costa, M. Hanlon, A.J. Spencer, J.D. Honeycutt, D.H. Wyllie, S.C. Gilbert, M. Bregu, A.V. Hill, Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass, Sci. Transl. Med. 2 (19) (2010) 19ra12.
110. Y.C. Kim, F.S. Quan, R.W. Compans, S.M. Kang, M.R. Prausnitz, Stability kinetics of influenza vaccine coated onto microneedles during drying and storage, Pharm. Res. 28 (1) (2010) 135-144.
111. V. Saluja, J.P. Amorij, J.C. Kapteyn, A.H. de Boer, H.W. Frijlink, W.L. Hinrichs, A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation, J. Control. Release 144 (2) (2010) 127-133.
112. J.L. Burger, S.P. Cape, C.S. Braun, D.H. McAdams, J.A. Best, P. Bhagwat, P. Pathak, L.G. Rebits, R.E. Sievers, Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine, J. Aerosol Med. Pulm. Drug Deliv. 21 (1) (2008) 25-34.
113. H.W. Kim, J.G. Canchola, C.D. Brandt, G. Pyles, R.M. Chanock, K. Jensen, R.H. Parrott, Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine, Am. J. Epidemiol. 89 (4) (1969) 422-434.
114. A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, C.E. Stewart, An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine, Am. J. Epidemiol. 89 (4) (1969) 405-421.
115. E.P. van Puijenbroek, A.C. van Grootheest, Monitoring adverse events of vaccines against Mexican flu, Int. J. Risk Saf. Med. 23 (2) (2011) 81-87.
116. B.N. Lambrecht, M. Kool, M.A. Willart, H. Hammad, Mechanism of action of clinically approved adjuvants, Curr. Opin. Immunol. 21 (1) (2009) 23-29.
117. B. Pulendran, Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology, Nat. Rev. Immunol. 9 (10) (2009) 741-747.
118. K. Kelly, A. Loskutov, D. Zehrung, K. Puaa, P. LaBarre, N. Muller, W. Guiqiang, H.G. Ding, D. Hu, W.C. Blackwelder, Preventing contamination between injections with multiple-use nozzle needle-free injectors: a safety trial, Vaccine 26 (10) (2008) 1344-1352.
119. J.K. Simon, M. Carter, M.F. Pasetti, M.B. Sztein, K. Kotloff, B.G. Weniger, J.D. Campbell, M.M. Levine, Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector, Vaccine 29 (51) (2011) 9544-9550.
120. P. Van Damme, F. Oosterhuis-Kafeja, M. Van der Wielen, Y. Almagor, O. Sharon, Y. Levin, Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults, Vaccine 27 (3) (2009) 454-459.
121. Sanofi, http://www.sanofipasteur.com/. (2011).
122. H.J. Hirschberg, G.G. van de Wijdeven, A.B. Kelder, G.P. van den Dobbelsteen, G.F. Kersten, Bioneedles as vaccine carriers, Vaccine 26 (19) (2008) 2389-2397.
123. E. Mallet, B.H. Belohradsky, R. Lagos, L. Gothefors, P. Camier, J.P. Carriere, G. Kanra, A. Hoffenbach, J. Langue, F. Undreiner, F. Roussel, P. Reinert, C.E. Flodmark, S. Stojanov, J. Liese, M.M. Levine, A. Munoz, F. Schodel, L. Hessel, A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety, Vaccine 22 (11-12) (2004) 1343-1357.
124. M. Singh, X.M. Li, J.P. McGee, T. Zamb, W. Koff, C.Y. Wang, D.T. O'Hagan, Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice, Vaccine 15 (5) (1997) 475-481.
125. M. Singh, X.M. Li, H. Wang, J.P. McGee, T. Zamb, W. Koff, C.Y. Wang, D.T. O'Hagan, Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine, Infect. Immun. 65 (5) (1997) 1716-1721.
126. M. Ruberti, L.K. De Melo, S.A. Dos Santos, I.T. Brandao, E.G. Soares, C.L. Silva, J.M. Junior, Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention, J. Drug Target. 12 (4) (2004) 195-203.
127. R.J. Raghuvanshi, A. Mistra, G.P. Talwar, R.J. Levy, V. Labhasetwar, Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid, J. Microencapsul. 18 (6) (2001) 723-732.
128. F.O. Nestle, P. Di Meglio, J.Z. Qin, B.J. Nickoloff, Skin immune sentinels in health and disease, Nat. Rev. Immunol. 9 (10) (2009) 679-691.
129. S.M. Bal, Z. Ding, E. van Riet, W. Jiskoot, J.A. Bouwstra, Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J. Control. Release 148 (3) (2010) 266-282.
130. S.A. Frech, H.L. Dupont, A.L. Bourgeois, R.McKenzie, J. Belkind-Gerson, J.F. Figueroa, P.C. Okhuysen, N.H. Guerrero, F.G. Martinez-Sandoval, J.H. Melendez-Romero, Z.D. Jiang, E.J. Asturias, J. Halpern, O.R. Torres, A.S. Hoffman, C.P. Villar, R.N. Kassem, D.C. Flyer, B.H. Andersen, K. Kazempour, S.A. Breisch, G.M. Glenn, Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial, Lancet 371 (9629) (2008) 2019-2025.
131. K. van der Maaden, W. Jiskoot, J.A. Bouwstra, Microneedles for (trans)dermal drug delivery, J. Control. Release 161 (2012) 649-659.
132. S.P. Sullivan, D.G. Koutsonanos, M. Del Pilar Martin, J.W. Lee, V. Zarnitsyn, S.O. Choi, N. Murthy, R.W. Compans, I. Skountzou, M.R. Prausnitz, Dissolving polymer microneedle patches for influenza vaccination, Nat. Med. 16 (8) (2010) 915-920.
133. M.L. Crichton, A. Ansaldo, X. Chen, T.W. Prow, G.J. Fernando, M.A. Kendall, The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine, Biomaterials 31 (16) (2010) 4562-4572.
134. W.C. Weldon, M.P. Martin, V. Zarnitsyn, B. Wang, D. Koutsonanos, I. Skountzou, M.R. Prausnitz, R.W. Compans, Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity, Clin. Vaccine Immunol. 18 (4) (2011) 647-654.
135. S.M. Bal, J. Caussin, S. Pavel, J.A. Bouwstra, In vivo assessment of safety of microneedle arrays in human skin, Eur. J. Pharm. Sci. 35 (3) (2008) 193-202.
136. J.C. Birchall, R. Clemo, A. Anstey, D.N. John, Microneedles in clinical practice - an exploratory study into the opinions of healthcare professionals and the public, Pharm. Res. 28 (1) (2011) 95-106.
137. S.M. Bal, B. Slutter, E. van Riet, A.C. Kruithof, Z. Ding, G.F. Kersten, W. Jiskoot, J.A. Bouwstra, Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations, J. Control. Release 142 (3) (2010) 374-383.
138. J.M. Song, Y.C. Kim, P.G. Barlow, M.J. Hossain, K.M. Park, R.O. Donis, M.R. Prausnitz, R.W. Compans, S.M. Kang, Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles, Antiviral Res. 88 (2) (2010) 244-247.
139. M. Rescigno, M. Urbano, B. Valzasina, M. Francolini, G. Rotta, R. Bonasio, F. Granucci, J.P. Kraehenbuhl, P. Ricciardi-Castagnoli, Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria, Nat. Immunol. 2 (4) (2001) 361-367.
140. D.J. Brayden, M.A. Jepson, A.W. Baird, Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting, Drug Discov. Today 10 (17) (2005) 1145-1157.
141. K.L. Kotloff, D.N. Taylor, M.B. Sztein, S.S.Wasserman, G.A. Losonsky, J.P. Nataro, M. Venkatesan, A. Hartman, W.D. Picking, D.E. Katz, J.D. Campbell, M.M. Levine, T.L. Hale, Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strainWRSS1 in healthy adults, Infect. Immun. 70 (4) (2002) 2016-2021.
142. M.F. Pasetti, J.K. Simon, M.B. Sztein, M.M. Levine, Immunology of gut mucosal vaccines, Immunol. Rev. 239 (1) (2011) 125-148.
143. W.A. Bakker, Y.E. Thomassen, A.G. Van't Oever, J. Westdijk, M.G. van Oijen, L.C. Sundermann, P. Van't Veld, E. Sleeman, F.W. van Nimwegen, A. Hamidi, G.F. Kersten, N. van den Heuvel, J.T. Hendriks, L.A. van der Pol, Inactivated polio vaccine development for technology transfer using attenuated Sabin
144. M.M. Levine, Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine, BMC Biol. 8 (2010) 129.
145. A. Azizi, A. Kumar, F. Diaz-Mitoma, J. Mestecky, Enhancing oral vaccine potency by targeting intestinal M cells, PLoS Pathog. 6 (11) (2010) e1001147.
146. J.P. Amorij, T.A. Westra, W.L. Hinrichs, A. Huckriede, H.W. Frijlink, Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model, Vaccine 26 (1) (2007) 67-76.
147. V. Saluja, M.R. Visser, M.L. van Roosmalen, K. Leenhouts, A. Huckriede, W.L. Hinrichs, H.W. Frijlink, Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles, Eur. J. Pharm. Biopharm. 76 (3) (2010) 470-474.
148. B. Slutter, L. Plapied, V. Fievez, M.A. Sande, A. des Rieux, Y.J. Schneider, E. Van Riet,W. Jiskoot, V. Preat, Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination, J. Control. Release 138 (2) (2009) 113-121.
149. J.B. Sun, C. Czerkinsky, J. Holmgren, Sublingual 'oral tolerance' induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells, Scand. J. Immunol. 66 (2-3) (2007) 278-286.
150. N. Cuburu, M.N. Kweon, J.H. Song, C. Hervouet, C. Luci, J.B. Sun, P. Hofman, J. Holmgren, F. Anjuere, C. Czerkinsky, Sublingual immunization induces broad-based systemic and mucosal immune responses in mice, Vaccine 25 (51) (2007) 8598-8610.
151. J.H. Song, H.H. Nguyen, N. Cuburu, T. Horimoto, S.Y. Ko, S.H. Park, C. Czerkinsky, M.N. Kweon, Sublingual vaccination with influenza virus protects mice against lethal viral infection, Proc. Natl. Acad. Sci. U. S. A. 105 (5) (2008) 1644-1649.
152. C. Desvignes, F. Esteves, N. Etchart, C. Bella, C. Czerkinsky, D. Kaiserlian, The murine buccal mucosa is an inductive site for priming class I-restricted CD8+ effector T cells in vivo, Clin. Exp. Immunol. 113 (3) (1998) 386-393.
153. N. Etchart, P.O. Desmoulins, K. Chemin, C. Maliszewski, B. Dubois, F. Wild, D. Kaiserlian, Dendritic cells recruitment and in vivo priming of CD8+CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein, J. Immunol. 167 (1) (2001) 384-391.
154. S. Senel, M. Kremer, K. Nagy, C. Squier, Delivery of bioactive peptides and proteins across oral (buccal) mucosa, Curr. Pharm. Biotechnol. 2 (2) (2001) 175-186.
155. J.D. Smart, Buccal drug delivery, Expert Opin. Drug Deliv. 2 (3) (2005) 507-517.
156. A.W. Wheeler, Formulation and delivery of therapeutic allergy vaccines, Arb. Paul Ehrlich Inst. Bundesamt Sera Impfstoffe Frankf. A.M. (93) (1999) 257-264 discussion 264-255.
157. C.F. Flach, N. Svensson, M. Blomquist, A. Ekman, S. Raghavan, J. Holmgren, A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori, Vaccine 29 (6) (2011) 1235-1241.
158. C. Czerkinsky, N. Cuburu, M.N. Kweon, F. Anjuere, J. Holmgren, Sublingual vaccination, Hum. Vaccin. 7 (1) (2011) 110-114.
159. C.F. Huang, T.C. Wu, C.C. Wu, C.C. Lee, W.T. Lo, K.S. Hwang, M.L. Hsu, H.J. Peng, Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis, APMIS 119 (7) (2011) 468-478.
160. T.J. Powell, T. Strutt, J. Reome, J.A. Hollenbaugh, A.D. Roberts, D.L. Woodland, S.L. Swain, R.W. Dutton, Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus, J. Immunol. 178 (2) (2007) 1030-1038.
161. T. Ichinohe, H.K. Lee, Y. Ogura, R. Flavell, A. Iwasaki, Inflammasome recognition of influenza virus is essential for adaptive immune responses, J. Exp. Med. 206 (1) (2009) 79-87.
162. B. Slütter, N. Hagenaars, W. Jiskoot, Rational design of nasal vaccines, J. Drug Target. 16 (1) (2008) 1-17.
163. N. Csaba, M. Garcia-Fuentes, M.J. Alonso, Nanoparticles for nasal vaccination, Adv. Drug Deliv. Rev. 61 (2) (2009) 140-157.
164. T. Nochi, Y. Yuki, H. Takahashi, S. Sawada, M. Mejima, T. Kohda, N. Harada, I.G. Kong, A. Sato, N. Kataoka, D. Tokuhara, S. Kurokawa, Y. Takahashi, H. Tsukada, S. Kozaki, K. Akiyoshi, H. Kiyono, Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines, Nat. Mater. 9 (7) (2010) 572-578.
165. B. Heurtault, B. Frisch, F. Pons, Liposomes as delivery systems for nasal vaccination: strategies and outcomes, Expert Opin. Drug Deliv. 7 (7) (2010) 829-844.
166. M.G. Cusi, Applications of influenza virosomes as a delivery system, Hum. Vaccin. 2 (1) (2006) 1-7.
167. B. Slütter, S.M. Bal, I. Que, E. Kaijzel, C. Lowik, J. Bouwstra, W. Jiskoot, Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol. Pharm. 7 (6) (2010) 2207-2215.
168. S.P. Vyas, P.N. Gupta, Implication of nanoparticles/microparticles in mucosal vaccine delivery, Expert Rev. Vaccines 6 (3) (2007) 401-418.
169. Y. Fujimura, M. Takeda, H. Ikai, K. Haruma, T. Akisada, T. Harada, T. Sakai, M. Ohuchi, The role ofM cells of human nasopharyngeal lymphoid tissue in influenza virus sampling, Virchows Arch. 444 (1) (2004) 36-42.
170. D.T. O'Hagan, M. Singh, J.B. Ulmer, Microparticle-based technologies for vaccines, Methods 40 (1) (2006) 10-19.
171. M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, T. Linder, C. Spyr, R. Steffen, Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland, N. Engl. J. Med. 350 (9) (2004) 896-903.
172. D.J. Lewis, Z. Huo, S. Barnett, I. Kromann, R. Giemza, E. Galiza, M. Woodrow, B. Thierry-Carstensen, P. Andersen, D. Novicki, G. Del Giudice, R. Rappuoli, Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin, PLoS One 4 (9) (2009) e6999.
173. F. Blank, P. Stumbles, C. von Garnier, Opportunities and challenges of the pulmonary route for vaccination, Expert Opin. Drug Deliv. 8 (5) (2011) 547-563.
174. D. Lu, A.J. Hickey, Pulmonary vaccine delivery, Expert Rev. Vaccines 6 (2) (2007) 213-226.
175. P.L. Ogra, H. Faden, R.C. Welliver, Vaccination strategies for mucosal immune responses, Clin. Microbiol. Rev. 14 (2) (2001) 430-445.
176. F.T. Cutts, C.J. Clements, J.V. Bennett, Alternative routes of measles immunization: a review, Biologicals 25 (3) (1997) 323-338.
177. J.S. Patton, P.R. Byron, Inhaling medicines: delivering drugs to the body through the lungs, Nat. Rev. Drug Discov. 6 (1) (2007) 67-74.
178. L. Garcia-Contreras, Y.L. Wong, P. Muttil, D. Padilla, J. Sadoff, J. Derousse, W.A. Germishuizen, S. Goonesekera, K. Elbert, B.R. Bloom, R. Miller, P.B. Fourie, A. Hickey, D. Edwards, Immunization by a bacterial aerosol, Proc. Natl. Acad. Sci. U. S. A. 105 (12) (2008) 4656-4660.
179. J.P. Amorij, V. Saluja, A.H. Petersen, W.L. Hinrichs, A. Huckriede, H.W. Frijlink, Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice, Vaccine 25 (52) (2007) 8707-8717.
180. S.A. Audouy, G. van der Schaaf, W.L. Hinrichs, H.W. Frijlink, J. Wilschut, A. Huckriede, Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization, Vaccine 29 (26) (2011) 4345-4352.
181. K.O. Kisich, M.P. Higgins, I. Park, S.P. Cape, L. Lindsay, D.J. Bennett, S. Winston, J. Searles, R.E. Sievers, Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation, Vaccine 29 (5) (2011) 905-912.
182. W.H. Lin, D.E. Griffin, P.A. Rota, M. Papania, S.P. Cape, D. Bennett, B. Quinn, R.E. Sievers, C. Shermer, K. Powell, R.J. Adams, S. Godin, S. Winston, Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques, Proc. Natl. Acad. Sci. U. S. A. 108 (7) (2011) 2987-2992.
183. R.D. de Vries, K.J. Stittelaar, A.D. Osterhaus, R.L. de Swart, Measles vaccination: new strategies and formulations, Expert Rev. Vaccines 7 (8) (2008) 1215-1223.
184. WHO, Measles aerosol initiative, http://www.who.int/immunization- delivery/new-vaccines/technologies-aerosol/en/2002.
185. C.A. Siegrist, R. Aspinall, B-cell responses to vaccination at the extremes of age, Nat. Rev. Immunol. 9 (3) (2009) 185-194.
186. A.T. Kamath, A.F. Rochat, M.P. Valenti, E.M. Agger, K. Lingnau, P. Andersen, P.H. Lambert, C.A. Siegrist, Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant, PLoS One 3 (11) (2008) e3683.
187. K. Haberthur, F. Engelman, A. Barron, I. Messaoudi, Immune senescence in aged nonhuman primates, Exp. Gerontol. 45 (9) (2010) 655-661.
188. N.M. Bouvier, A.C. Lowen, Animal models for influenza virus pathogenesis and transmission, Viruses 2 (8) (2010) 1530-1563.
189. N. Saubi, E.J. Im, R. Fernandez-Lloris, O. Gil, P.J. Cardona, J.M. Gatell, T. Hanke, J. Joseph, Newborn mice vaccination with BCG.HIVA(2)(2)(2) +MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes, Clin. Dev. Immunol. 2011 (2011) 516219.
190. D.C. Nguyen, F. Masseoud, X. Lu, F. Scinicariello, S. Sambhara, R. Attanasio, 17beta-Estradiol restores antibody responses to an influenza vaccine in a postmenopausal mouse model, Vaccine 29 (14) (2011) 2515-2518.
191. S.A. Cormier, D. You, S. Honnegowda, The use of a neonatal mouse model to study respiratory syncytial virus infections, Expert Rev. Anti Infect. Ther. 8 (12) (2010) 1371-1380.